卵巢癌肉瘤的现实世界经验和预后因素:来自中国的单中心回顾性研究

Wanwan Ji1, Yunmei Zhuo2, Xianzhong Cheng3

  • 1Department of Surgery, Jiangsu Cancer Hospital, Jiangsu Institute of Cancer Research, The Affiliated Cancer Hospital of Nanjing Medical University, Nanjing, China.

Frontiers in oncology
|June 25, 2025
PubMed
概括

卵巢癌瘤 (OCS) 是罕见的. 这项研究确定了年龄,瘤大小,Ki-67和骨作为OCS的潜在预后因素. 患有同源重组缺乏症 (HRD) 的患者可能受益于PARP抑制剂.